Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8909197 | 0.85 | ALDH1A1 (0.54) | PPARGHSP90AA1ESR2TDP1 | |
| SCHEMBL889020 | 0.81 | ALDH1A1 (0.41) | HSP90AA1ESR2TDP1 | |
| SCHEMBL8910012 | 0.79 | PDE3B (0.47) | HSP90AA1ESR2TDP1 | |
| SCHEMBL3982935 | 0.78 | THRA (0.54) | FFAR1 | |
| SCHEMBL889043 | 0.78 | ALDH1A1 (0.41) | HSP90AA1ESR2TDP1 | |
| SCHEMBL889048 | 0.78 | RAD52 (0.43) | TDP1 | |
| SCHEMBL889001 | 0.78 | HSD17B10 (0.47) | HSP90AA1ESR2TDP1 | |
| SCHEMBL12213873 | 0.77 | ALDH1A1 (0.46) | HSP90AA1ESR2TDP1 | |
| SCHEMBL17702654 | 0.77 | TUBB4A (0.44) | — | |
| Hydrochloric Acid SCHEMBL11366200 | 0.76 | HSD17B10 (0.46) | HSP90AA1ESR2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188132-B2 | Linked dibenzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | FFAR1 2727/4885PPARG 1585/4885FFAR4 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.